Junshi’s PD-1 among seven new products recommended by EMA’s CHMP

Although the headline news from the latest meeting of EMA’s CHMP was the agency’s rebuff of Alzheimer’s therapy Leqembi, the committee also recommended approval of seven new medicines label extensions for 11 approved products.

Highlights from CHMP’s July meeting include a positive opinion for Loqtorzi toripalimab from Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877; Shanghai:688180) to treat first-line nasopharyngeal cancer and esophageal squamous cell carcinoma (ESCC), in combinations with chemotherapy. ...